<?xml version="1.0" encoding="UTF-8"?>
<table xmlns="http://www.w3.org/1999/xhtml">
 <caption>PMC6507620</caption>
 <thead>
  <tr>
   <th>label</th>
   <th>caption</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>
    <a href="table_1.xml">FIGURE 1</a>
   </td>
   <td>Chemical structure of talinolol (TAL, M.W: 363.5, pKa: 9.4).</td>
  </tr>
  <tr>
   <td>
    <a href="table_2.xml">FIGURE 2</a>
   </td>
   <td>Typical physical appearance of the “Formulations” (F) and th ... </td>
  </tr>
  <tr>
   <td>
    <a href="table_3.xml">FIGURE 3</a>
   </td>
   <td>The effect of hydrophilic compositions on the particle size ... </td>
  </tr>
  <tr>
   <td>
    <a href="table_4.xml">FIGURE 4</a>
   </td>
   <td>Transmission electron microscopy (TEM) images of the droplet ... </td>
  </tr>
  <tr>
   <td>
    <a href="table_5.xml">FIGURE 5</a>
   </td>
   <td>In vitro release of TAL from the pure raw TAL powder, market ... </td>
  </tr>
  <tr>
   <td>
    <a href="table_6.xml">FIGURE 6</a>
   </td>
   <td>In vitro release of TAL from the pure raw TAL powder, market ... </td>
  </tr>
  <tr>
   <td>
    <a href="table_7.xml">FIGURE 7</a>
   </td>
   <td>The % TAL solubilized in aqueous phase (AP), pellet phase (P ... </td>
  </tr>
  <tr>
   <td>
    <a href="table_8.xml">FIGURE 8</a>
   </td>
   <td>Apparent permeability of TAL ( A: % cumulative drug concentr ... </td>
  </tr>
  <tr>
   <td>
    <a href="table_9.xml">FIGURE 9</a>
   </td>
   <td>In vitro toxicity test of pure TAL, Blank SNEDDS (drug free) ... </td>
  </tr>
  <tr>
   <td>
    <a href="table_10.xml">FIGURE 10</a>
   </td>
   <td>Plasma concentration– time profiles of TAL after a single or ... </td>
  </tr>
 </tbody>
</table>
